Hurdles and leaps for protein therapeutics: Cytokines and inflammation

Annals of the New York Academy of Sciences

Volumn 1182, Issue , 2009, Pages 146-160

  Kozlowski, Steven ^a   Cherney, Barry ^b   Donnelly, Raymond P ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Center for Drug Evaluation and Research   (United States)

Author keywords

Biotechnology; Cytokines; Inflammation; Manufacturing; Pharmaceutical development

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN3 INTERFERON; ALTEPLASE; BASILIXIMAB; BETA INTERFERON; BETA1A INTERFERON; CERTOLIZUMAB PEGOL; CONSENSUS INTERFERON; CYTOKINE; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; GAMMA INTERFERON; GAMMA1B INTERFERON; INFLIXIMAB; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 4; INTERLEUKIN 7; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 2; RILONACEPT; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ALBERS SCHOENBERG DISEASE; BIOLOGICAL ACTIVITY; CELL ACTIVITY; CHRONIC GRANULOMATOUS DISEASE; CINCA SYNDROME; CONDYLOMA ACUMINATUM; CONFERENCE PAPER; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GENETIC DISORDER; GENETIC ENGINEERING; HAIRY CELL LEUKEMIA; HEPATITIS C; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; LUNG NON SMALL CELL CANCER; METASTASIS; MUCKLE WELLS SYNDROME; MULTIPLE SCLEROSIS; NONHUMAN; RHEUMATOID ARTHRITIS; TH1 CELL; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 73849113385     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05158.x     Document Type: Conference Paper

References (85)

1. Sikora, K. 1980. Does interferon cure cancer? Br. Med. J. 281: 855-858.
2. Kirkwood, J.M. & M.S. Ernstoff. 1984. Interferons in the treatment of human cancer. J. Clin. Oncol. 2: 336-352.
3. Dinarello, C.A. 1994. The IL-1 family: 10 years of discovery. FASEB J. 8: 1314-1325.
4. Dinarello, C.A. 1984. IL-1. Rev. Infect. Dis. 6: 51-95.
5. 2002. Anakinra (Kineret) for rheumatoid arthritis. Med. Lett. Drugs Ther. 44: 18-19.
6. Kapur, S. & M.E. Bonk. 2009. Rilonacept (Arcalyst), an IL-1 trap for the treatment of cryopyrinassociated periodic syndromes. P. T. 34: 138-141.
7. Foster, D. et al. 2004. Cytokine-receptor pairing: Accelerating discovery of cytokine function. Nat. Rev. Drug Discov. 3: 160-170.
8. Bickston, S.J. & F. Cominelli. 2000. Recombinant IL-10 for the treatment of active Crohn's disease: lessons in biologic therapy. Gastroenterology 119: 1781-1783.
9. Leonard, J.P. et al. 1997. Effects of single-dose IL-12 exposure on IL-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548.
10. NYAS. 2009. CytokineTherapies:NovelApproaches for Clinical Indications. eBriefing.
11. Cantell, K. et al. 1974. Human leukocyte interferon: production, purification, stability, and animal experiments. In Vitro Monogr. 35-38.
12. Gibbs, C.J., Jr. et al. 1985. Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone. N. Engl. J.Med. 313: 734-738.
13. Singer,M.&P. Berg. 1976.RecombinantDNA:NIH guidelines. Science 193: 186-188.
14. Peters, M. et al. 1986. Immunologic effects of interferon-alpha in man: Treatment with human recombinant interferon-alpha suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. J. Immunol. 137: 3147-3152.
15. Smith, S.L. 1996. Ten years of Orthoclone OKT3 (muromonab-CD3): A review. J. Transpl. Coord. 6: 109-119.
16. Spellman,M.W. et al. 1989. Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells. J. Biol. Chem. 264: 14100-14111.
17. Cox, M.M. 2008. Progress on baculovirus-derived influenza vaccines. Curr. Opin. Mol. Ther. 10: 56-61.
18. Kling, J. 2009. First US approval for a transgenic animal drug. Nat. Biotechnol. 27: 302-304.
19. Yano, A. & M. Takekoshi. 2004. Transgenic plantderived pharmaceuticals-the practical approach? Expert. Opin. Biol. Ther. 4: 1565-1568.
20. O'Connor, J.V. 1993. The use of peptide mapping for the detection of heterogeneity in recombinant DNAderived proteins. Biologicals 21: 111-117.
21. Cho, A. & D. Normile. 2002. Nobel Prize in Chemistry. Mastering macromolecules. Science 298: 527-528.
22. ICH. 2004. Q5E Comparability of Biotechnological/ Biological Products Subject to Changes in their Manufacturing Process.
23. U.S. FDA. 1996. FDA Guidance Concerning Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnologyderived Products.
24. U.S. FDA. 1997. Guidance for Industry: Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products.
25. U.S. FDA. 1997. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use.
26. ICH. 1999. Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.
27. ICH. 1995. Q5B Analysis of the Expression Construct in Cells Used for the Production of r-DNA Derived Protein Products and Q5C Stability Testing for Biotechnology/Biological Products.
28. ICH. 1997. Q5A Viral Safety Evaluation of Biotechnology products derived from lines of Human or Animal Origin and Derivation and Q5D Characterization of Cell Substrates Used for the Production of Biotechnology/Biological Products.
29. U.S. FDA. 2004. Guidance for Industry PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance.
30. ICH. 2008. Q8(R1) Pharmaceutical Development Revision 1.
31. ICH. 2006. Q9: Quality Risk Management.
32. Rathore, A.S. & H. Winkle. 2009. Quality by design for biopharmaceuticals. Nat. Biotechnol. 27: 26-34.
33. Rao, G., A. Moreira & K. Brorson. 2009. Disposable bioprocessing: The future has arrived. Biotechnol. Bioeng. 102: 348-356.
34. Zheng, T. et al. 2001. IL-11: insights in asthma from overexpression transgenic modeling. J. Allergy Clin. Immunol. 108: 489-496.
35. Herrlinger, K.R. et al. 2006. Randomized, double blind controlled trial of subcutaneous recombinant human IL-11 versus prednisolone in active Crohn's disease. Am. J. Gastroenterol. 101: 793-797.
36. Paul, W.E. 1989. Pleiotropy and redundancy: T cellderived lymphokines in the immune response. Cell 57: 521-524.
37. Mosmann, T.R. et al. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136: 2348-2357.
38. Mosmann, T.R. & S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17: 138-146.
39. Maher, D.W. et al. 1991. Human IL-4: An immunomodulator with potential therapeutic applications. Prog. Growth Factor Res. 3: 43-56.
40. Vokes, E.E. et al. 1998. A phase II study of recombinant human IL-4 for advanced or recurrent nonsmall cell lung cancer. Cancer J. Sci. Am. 4: 46-51.
41. Seder, R.A. & W.E. Paul. 1994. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12: 635-673.
42. Bashyam, H. 2007. Th1/Th2 cross-regulation and the discovery of IL-10. J. Exp. Med. 204: 237.
43. Grool, T.A. et al. 1998. Anti-inflammatory effect of IL-10 in rabbit immune complex-induced colitis. Scand. J. Gastroenterol. 33: 754-758.
44. Kennedy, R.J. et al. 2000. IL-10-deficient colitis: new similarities to human inflammatory bowel disease. Br. J. Surg. 87: 1346-1351.
45. Stouthard, J.M. et al. 1996. Recombinant human IL-6 in metastatic renal cell cancer: A phase II trial. Br. J. Cancer 73: 789-793.
46. Gery, I., R.K. Gershon & B.H. Waksman. 1972. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J. Exp. Med. 136: 128-142.
47. Smith, J.W., 2nd et al. 1992. The toxic and hematologic effects of IL-1 alpha administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 10: 1141-1152.
48. Hallegua, D.S. & M.H. Weisman. 2002. Potential therapeutic uses of IL-1 receptor antagonists in human diseases. Ann. Rheum. Dis. 61: 960-967.
49. Hoffman, H.M. 2009. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin. Biol. Ther. 9: 519-531.
50. Clark, I.A. 2007. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 18: 335-343.
51. Brophy, L. 2001. Tumor necrosis. In Biotherapy A Comprehensive Overview. P.T. Reiger, ed. Jones and Bartlett. Sudbury, MA.
52. 2007. 200-World's Best-SellingMedicines.MedAd-News, July.
53. Leombruno, J.P., T.R. Einarson & E.C. Keystone. 2009. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposureadjusted pooled analyses of serious adverse events. Ann. Rheum. Dis. 68: 1136-1145.
54. Huggett, B. 2008. FDA probes TNF blockers. Nat. Biotechnol. 26: 845.
55. 1986. Interferon for treatment of hairy-cell leukemia. Med. Lett. Drugs Ther. 28: 78-79.
56. Baron, S. et al. 1991. The interferons.Mechanisms of action and clinical applications. JAMA 266: 1375-1383.
57. Saadeh, S. & G.L. Davis. 2004. The evolving treatment of chronic hepatitis C: where we stand a decade out. Cleve. Clin. J. Med. 71(Suppl 3): S3-7.
58. 1993. Interferon beta-1B for multiple sclerosis. Med. Lett. Drugs Ther. 35: 61-62.
59. Shankar, L., E.A. Gerritsen & L.L. Key Jr. 1997. (No title available.) BioDrugs 7: 23-29.
60. Gillis, S. 1983. IL-2: biology and biochemistry. J. Clin. Immunol. 3: 1-13.
61. Atkins,M.B. et al. 1999. High-dose recombinant IL-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17: 2105-2116.
62. Gale, D.M. & P. Sorokin. 2001. Hurdles and leaps for protein therapeutics: Cytokines and inflammation. In Biotherapy A Comprehensive Overview. P.T. Reiger, ed.: 1-15. Jones and Bartlett. Sudbury, MA.
63. Romo de Vivar Chavez, A. et al. 2009. The biology of IL-2 efficacy in the treatment of patients with renal cell carcinoma. Med. Oncol. 26(Suppl 1): 3-12.
64. Smith, K.A. 1997. Rational IL-2 therapy. Cancer J Sci Am. 3(Suppl 1): S137-S140.
65. DiMasi, J.A., R.W. Hansen & H.G. Grabowski. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22: 151-185.
66. Basu, A., J.K. Krady & S.W. Levison. 2004. IL-1: A master regulator of neuroinflammation. J. Neurosci. Res. 78: 151-156.
67. Couper, K.N., D.G. Blount & E.M. Riley. 2008. IL-10: The master regulator of immunity to infection. J. Immunol. 180: 5771-5777.
68. McLaren, J.E. & D.P. Ramji. 2009. Interferon gamma: A master regulator of atherosclerosis. Cytokine Growth Factor Rev. 20: 125-135.
69. Halsey, T.A. et al. 2007. A functional map of NFkappaB signaling identifies novel modulators and multiple system controls. Genome Biol. 8: R104.
70. Kim, H.R. et al. 2008. IL-7 and IL-15: biology and roles in T-Cell immunity in health and disease. Crit. Rev. Immunol. 28: 325-339.
71. Korn, T. et al. 2009. IL-17 and Th17 cells. Annu. Rev. Immunol. 27: 485-517.
72. Neurath, M.F. 2007. IL-23: A master regulator in Crohn disease. Nat. Med. 13: 26-28.
73. Deenick, E.K. & S.G. Tangye. 2007. Autoimmunity: IL-21: A new player in Th17-cell differentiation. Immunol. Cell Biol. 85: 503-505.
74. Kotenko, S.V. et al. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4: 69-77.
75. Aggarwal, B.B. et al. 2002. The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr. Drug Targets Inflamm Allergy 1: 327-341.
76. Genentech. 2003. A Study of rhuMAb VEGF (Bevacizumab) in Combination with Chemotherapy in Patients with Previously Treated Breast Cancer: RhuMAb VEGF-CSR AVF2119g Final. Clinical Study Report Synopsis.
77. Jain, R.K. et al. 2006. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3: 24-40.
78. Reich, K.,U.Yasothan&P. Kirkpatrick. 2009. Ustekinumab. Nat. Rev. Drug Discov. 8: 355-356.
79. Scheinecker, C. et al. 2009. Tocilizumab. Nat. Rev. Drug Discov. 8: 273-274.
80. 1998. Etanercept marketed for moderate, severe rheumatoid arthritis. Am. J. Health Syst. Pharm. 55: 2593.
81. Zhu, Y. et al. 2004. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alphaglucosidase improves the clearance of glycogen in pompe mice. J. Biol. Chem. 279: 50336-50341.
82. Elliott, S. et al. 2003. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol. 21: 414-421.
83. Wu,H. et al. 2007. Development ofmotavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368: 652-665.
84. Chang, C.C. et al. 1999. Evolution of a cytokine using DNA family shuffling. Nat. Biotechnol. 17: 793-797.
85. Brunton, S. 2008. Insulin delivery systems: Reducing barriers to insulin therapy and advancing diabetes mellitus treatment. Am. J. Med. 121: S35-S41.